Laboratorios Bago De Bolivia S.A. Sustainability Profile
Laboratorios Bago de Bolivia S.A., a prominent player in the pharmaceutical industry, is headquartered in Bolivia and operates extensively across the Andean region. Founded in 1995, the company has established itself as a leader in the development, manufacturing, and distribution of high-quality pharmaceutical products. Specialising in a diverse range of therapeutic areas, including cardiology, oncology, and infectious diseases, Laboratorios Bago is renowned for its commitment to innovation and quality. The company’s unique approach combines advanced technology with rigorous research, ensuring that its products meet the highest standards of efficacy and safety. With a strong market position, Laboratorios Bago de Bolivia S.A. has achieved significant milestones, including numerous certifications and partnerships that underscore its reputation for excellence in the pharmaceutical sector.
DitchCarbon Score
How does Laboratorios Bago De Bolivia S.A.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Laboratorios Bago De Bolivia S.A.'s score of 20 is lower than 82% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Laboratorios Bago De Bolivia S.A.'s reported carbon emissions
Laboratorios Bago De Bolivia S.A., headquartered in Bolivia, currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures in kg CO2e. Furthermore, there are no documented reduction targets or climate pledges associated with the company. As a current subsidiary, Laboratorios Bago De Bolivia S.A. may inherit climate commitments and emissions data from its parent organisation, Laboratorios Bago, but specific details regarding these cascaded data points are not available. The company appears to be in the early stages of establishing its climate strategy, with no clear initiatives or targets outlined at this time. In the broader context of the pharmaceutical industry, companies are increasingly focusing on sustainability and carbon reduction, often setting science-based targets to align with global climate goals. However, without specific commitments or data, it is challenging to assess Laboratorios Bago De Bolivia S.A.'s position within this evolving landscape.
How Carbon Intensive is Laboratorios Bago De Bolivia S.A.'s Industry?
How Carbon Intensive is Laboratorios Bago De Bolivia S.A.'s Location?
Laboratorios Bago De Bolivia S.A.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Laboratorios Bago De Bolivia S.A. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
